JP7068277B2 - Eaat3阻害剤としてのイミダゾール化合物 - Google Patents

Eaat3阻害剤としてのイミダゾール化合物 Download PDF

Info

Publication number
JP7068277B2
JP7068277B2 JP2019514255A JP2019514255A JP7068277B2 JP 7068277 B2 JP7068277 B2 JP 7068277B2 JP 2019514255 A JP2019514255 A JP 2019514255A JP 2019514255 A JP2019514255 A JP 2019514255A JP 7068277 B2 JP7068277 B2 JP 7068277B2
Authority
JP
Japan
Prior art keywords
tert
butyl
benzamide
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019514255A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532050A (ja
JP2019532050A5 (cg-RX-API-DMAC7.html
Inventor
ヘナー,マリウス
ヴィッヒマン,ユルゲン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2019532050A publication Critical patent/JP2019532050A/ja
Publication of JP2019532050A5 publication Critical patent/JP2019532050A5/ja
Application granted granted Critical
Publication of JP7068277B2 publication Critical patent/JP7068277B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2019514255A 2016-10-14 2017-10-11 Eaat3阻害剤としてのイミダゾール化合物 Expired - Fee Related JP7068277B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16193871 2016-10-14
EP16193871.7 2016-10-14
PCT/EP2017/075875 WO2018069362A1 (en) 2016-10-14 2017-10-11 Imidazole compounds as eaat3 inhibitors

Publications (3)

Publication Number Publication Date
JP2019532050A JP2019532050A (ja) 2019-11-07
JP2019532050A5 JP2019532050A5 (cg-RX-API-DMAC7.html) 2020-11-19
JP7068277B2 true JP7068277B2 (ja) 2022-05-16

Family

ID=57136749

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019514255A Expired - Fee Related JP7068277B2 (ja) 2016-10-14 2017-10-11 Eaat3阻害剤としてのイミダゾール化合物

Country Status (5)

Country Link
US (1) US10556870B2 (cg-RX-API-DMAC7.html)
EP (1) EP3526201B1 (cg-RX-API-DMAC7.html)
JP (1) JP7068277B2 (cg-RX-API-DMAC7.html)
CN (1) CN109563049B (cg-RX-API-DMAC7.html)
WO (1) WO2018069362A1 (cg-RX-API-DMAC7.html)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502148A (ja) 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのp2x3受容体アンタゴニスト
JP2011506520A (ja) 2007-12-17 2011-03-03 エフ.ホフマン−ラ ロシュ アーゲー 新規なイミダゾール置換アリールアミド
WO2014193248A1 (en) 2013-05-31 2014-12-04 The A2 Milk Company Limited Beta-casein a2 and prevention of inflammation of the bowel
JP2016529238A (ja) 2013-07-18 2016-09-23 ノバルティス アーゲー 補体因子d阻害剤としてのアミノメチル−ビアリール誘導体およびその使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882926A (en) * 1993-10-20 1999-03-16 Oregon Health Sciences University Excitatory amino acid transporter gene and uses
JP2006151954A (ja) 2004-10-27 2006-06-15 Taisho Pharmaceut Co Ltd アスパラギン酸誘導体
US7939556B2 (en) 2005-10-14 2011-05-10 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
ES2596706T3 (es) 2006-06-29 2017-01-11 F. Hoffmann-La Roche Ag Arilamidas con sustitución de tetrazol
KR101186704B1 (ko) 2007-10-04 2012-09-27 에프. 호프만-라 로슈 아게 테트라졸-치환된 아릴 아마이드 유도체 및 이의 용도
KR101405746B1 (ko) 2007-12-17 2014-06-10 에프. 호프만-라 로슈 아게 트리아졸 치환된 아릴아미드 유도체 및 p2x3 및/또는 p2x2/3 퓨린성 수용체 길항제로서의 용도
DK2234976T3 (da) 2007-12-17 2013-06-24 Hoffmann La Roche Nye pyrazol-substituerede arylamider
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
US20110237578A1 (en) 2008-09-18 2011-09-29 Zhi-Liang Wei Amide compounds, compositions and uses thereof
CA2741666C (en) 2008-10-31 2017-04-11 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
US10577332B2 (en) 2015-04-23 2020-03-03 Hoffmann-La Roche Inc. Tetrazole derivatives
CN107531642B (zh) 2015-06-04 2021-06-22 豪夫迈·罗氏有限公司 咪唑衍生物
JP6846363B2 (ja) 2015-07-14 2021-03-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 2−フェニル−6−イミダゾリル−ピリジン−4−カルボキサミド誘導体及びそのeaat3阻害剤としての使用
WO2017025523A1 (en) 2015-08-12 2017-02-16 F. Hoffmann-La Roche Ag Pyridine and pyrimidine derivatives
WO2017060202A1 (en) 2015-10-06 2017-04-13 F. Hoffmann-La Roche Ag Triazole derivatives
ITUB20154829A1 (it) 2015-10-27 2017-04-27 Giuseppe Galtieri Dispositivo ad impulsi dinamici da traffico veicolare e relativo kit.
EP3411365B1 (en) 2016-02-02 2019-11-20 H. Hoffnabb-La Roche Ag Pyrazol-pyridine derivatives as eaat3 inhibitors
CN109071451B (zh) 2016-05-27 2022-07-15 豪夫迈·罗氏有限公司 作为eaat3抑制剂的吡唑化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011502148A (ja) 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのp2x3受容体アンタゴニスト
JP2011506520A (ja) 2007-12-17 2011-03-03 エフ.ホフマン−ラ ロシュ アーゲー 新規なイミダゾール置換アリールアミド
WO2014193248A1 (en) 2013-05-31 2014-12-04 The A2 Milk Company Limited Beta-casein a2 and prevention of inflammation of the bowel
JP2016529238A (ja) 2013-07-18 2016-09-23 ノバルティス アーゲー 補体因子d阻害剤としてのアミノメチル−ビアリール誘導体およびその使用

Also Published As

Publication number Publication date
JP2019532050A (ja) 2019-11-07
US10556870B2 (en) 2020-02-11
EP3526201A1 (en) 2019-08-21
WO2018069362A1 (en) 2018-04-19
CN109563049B (zh) 2022-11-29
CN109563049A (zh) 2019-04-02
EP3526201B1 (en) 2020-11-18
US20190233379A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
JP7794910B2 (ja) Eaat2活性化因子およびその使用方法
JP6518789B2 (ja) 精神障害の処置において使用するためのテトラゾール誘導体
CN105793259A (zh) 氟-萘基衍生物
JP6877359B2 (ja) イミダゾール誘導体
EP3368522B1 (en) Pyridine or pyrimidine derivatives
JP6846363B2 (ja) 2−フェニル−6−イミダゾリル−ピリジン−4−カルボキサミド誘導体及びそのeaat3阻害剤としての使用
JP6905988B2 (ja) Eaat3阻害剤としてのピラゾール−ピリジン誘導体
JP6831376B2 (ja) トリアゾール誘導体
JP6936257B2 (ja) Eaat3阻害剤としてのピラゾール化合物
JP2018531253A6 (ja) トリアゾール誘導体
JP2019532050A (ja) Eaat3阻害剤としてのイミダゾール化合物
EP1539687A1 (en) Substituted glycine derivatives for use as medicaments
HK40004826B (en) Imidazole compounds as eaat3 inhibitors
HK40004826A (en) Imidazole compounds as eaat3 inhibitors
HK1262810B (en) Pyrazol compounds as eaat3 inhibitors
HK1262810A1 (en) Pyrazol compounds as eaat3 inhibitors
HK1081441B (zh) 对钙通道α-2-δ亚基具有亲合力的脯氨酸衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201005

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220314

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220405

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220428

R150 Certificate of patent or registration of utility model

Ref document number: 7068277

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees